133 related articles for article (PubMed ID: 34197084)
1. Neuroprotective Effects of Trehalose and Sodium Butyrate on Preformed Fibrillar Form of α-Synuclein-Induced Rat Model of Parkinson's Disease.
Kakoty V; K C S; Dubey SK; Yang CH; Taliyan R
ACS Chem Neurosci; 2021 Jul; 12(14):2643-2660. PubMed ID: 34197084
[TBL] [Abstract][Full Text] [Related]
2. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.
He Q; Koprich JB; Wang Y; Yu WB; Xiao BG; Brotchie JM; Wang J
Mol Neurobiol; 2016 May; 53(4):2258-68. PubMed ID: 25972237
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Effects of Selenium on Alpha-Synuclein Accumulation in Substantia Nigra Pars Compacta in a Rat Model of Parkinson's Disease: Behavioral and Biochemical Outcomes.
Salaramoli S; Joshaghani HR; Hosseini M; Hashemy SI
Biol Trace Elem Res; 2024 Mar; 202(3):1115-1125. PubMed ID: 37386228
[TBL] [Abstract][Full Text] [Related]
4. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease.
Zhang Y; Wu Q; Zhang L; Wang Q; Yang Z; Liu J; Feng L
Pharmacol Res; 2019 Dec; 150():104538. PubMed ID: 31707034
[TBL] [Abstract][Full Text] [Related]
5. α-Synuclein A53T Binds to Transcriptional Adapter 2-Alpha and Blocks Histone H3 Acetylation.
Lee JY; Kim H; Jo A; Khang R; Park CH; Park SJ; Kwag E; Shin JH
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065515
[TBL] [Abstract][Full Text] [Related]
6. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
[TBL] [Abstract][Full Text] [Related]
7. Trehalose Inhibits A53T Mutant α-Synuclein Overexpression and Neurotoxicity in Transduced PC12 Cells.
Zhao J; Zhi X; Pan L; Zhou P
Molecules; 2017 Aug; 22(8):. PubMed ID: 28786917
[TBL] [Abstract][Full Text] [Related]
8. Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease.
Palmas MF; Ena A; Burgaletto C; Casu MA; Cantarella G; Carboni E; Etzi M; De Simone A; Fusco G; Cardia MC; Lai F; Picci L; Tweedie D; Scerba MT; Coroneo V; Bernardini R; Greig NH; Pisanu A; Carta AR
Neurotherapeutics; 2022 Jan; 19(1):305-324. PubMed ID: 35072912
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: Modulation of histone deacetylase activity.
Sharma S; Taliyan R; Singh S
Behav Brain Res; 2015 Sep; 291():306-314. PubMed ID: 26048426
[TBL] [Abstract][Full Text] [Related]
10. Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.
Patterson JR; Duffy MF; Kemp CJ; Howe JW; Collier TJ; Stoll AC; Miller KM; Patel P; Levine N; Moore DJ; Luk KC; Fleming SM; Kanaan NM; Paumier KL; El-Agnaf OMA; Sortwell CE
Neurobiol Dis; 2019 Oct; 130():104525. PubMed ID: 31276792
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
[TBL] [Abstract][Full Text] [Related]
12. Curcumin affords neuroprotection and inhibits α-synuclein aggregation in lipopolysaccharide-induced Parkinson's disease model.
Sharma N; Nehru B
Inflammopharmacology; 2018 Apr; 26(2):349-360. PubMed ID: 29027056
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson's disease.
Pupyshev AB; Tikhonova MA; Akopyan AA; Tenditnik MV; Dubrovina NI; Korolenko TA
Pharmacol Biochem Behav; 2019 Feb; 177():1-11. PubMed ID: 30582934
[TBL] [Abstract][Full Text] [Related]
14. Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models.
Zhu Q; Zhuang XX; Chen JY; Yuan NN; Chen Y; Cai CZ; Tan JQ; Su HX; Lu JH
Phytomedicine; 2021 Jul; 87():153578. PubMed ID: 34038839
[TBL] [Abstract][Full Text] [Related]
15. Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice.
Fortuna JTS; Gralle M; Beckman D; Neves FS; Diniz LP; Frost PS; Barros-Aragão F; Santos LE; Gonçalves RA; Romão L; Zamberlan DC; Soares FAA; Braga C; Foguel D; Gomes FCA; De Felice FG; Ferreira ST; Clarke JR; Figueiredo CP
Behav Brain Res; 2017 Aug; 333():150-160. PubMed ID: 28668282
[TBL] [Abstract][Full Text] [Related]
16. Cilostazol Mediated Nurr1 and Autophagy Enhancement: Neuroprotective Activity in Rat Rotenone PD Model.
Hedya SA; Safar MM; Bahgat AK
Mol Neurobiol; 2018 Sep; 55(9):7579-7587. PubMed ID: 29429051
[TBL] [Abstract][Full Text] [Related]
17. Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.
Shahaduzzaman M; Nash K; Hudson C; Sharif M; Grimmig B; Lin X; Bai G; Liu H; Ugen KE; Cao C; Bickford PC
PLoS One; 2015; 10(2):e0116841. PubMed ID: 25658425
[TBL] [Abstract][Full Text] [Related]
18. Lactulose and Melibiose Inhibit α-Synuclein Aggregation and Up-Regulate Autophagy to Reduce Neuronal Vulnerability.
Chen CM; Lin CH; Wu YR; Yen CY; Huang YT; Lin JL; Lin CY; Chen WL; Chao CY; Lee-Chen GJ; Su MT; Chang KH
Cells; 2020 May; 9(5):. PubMed ID: 32429337
[TBL] [Abstract][Full Text] [Related]
19. Sodium butyrate causes α-synuclein degradation by an Atg5-dependent and PI3K/Akt/mTOR-related autophagy pathway.
Qiao CM; Sun MF; Jia XB; Shi Y; Zhang BP; Zhou ZL; Zhao LP; Cui C; Shen YQ
Exp Cell Res; 2020 Feb; 387(1):111772. PubMed ID: 31836471
[TBL] [Abstract][Full Text] [Related]
20. Squamosamide derivative FLZ protected dopaminergic neuron by activating Akt signaling pathway in 6-OHDA-induced in vivo and in vitro Parkinson's disease models.
Bao XQ; Kong XC; Kong LB; Wu LY; Sun H; Zhang D
Brain Res; 2014 Feb; 1547():49-57. PubMed ID: 24384139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
